SCHEDULE: BlackRock Discloses 13.1% Stake in Cytek Biosciences
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 13.1% beneficial ownership stake in Cytek Biosciences, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. beneficially owns an aggregate of 16,531,858 shares of Cytek Biosciences, Inc. Common Stock.
- This ownership represents 13.1% of the total outstanding shares of the class.
- BlackRock holds sole voting power over 16,227,448 shares and sole dispositive power over 16,531,858 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is classified as a parent holding company or control person.
- Several BlackRock subsidiaries are identified as having beneficial ownership, with BlackRock Fund Advisors specifically noted as owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as a major institutional investor maintains a significant stake, indicating continued confidence. However, the filing itself is a routine compliance disclosure and does not contain new strategic or financial information from the issuer.
Positives
- BlackRock, a prominent institutional investor, maintaining a significant 13.1% stake in Cytek Biosciences, Inc. indicates continued confidence in the company's long-term prospects.
- The disclosure provides transparency regarding a major institutional holder's position, which can be viewed positively by other investors.
Negatives
- No specific negatives are disclosed in this beneficial ownership report, as it is primarily a compliance filing.
Risks
- No specific risks related to Cytek Biosciences, Inc. are detailed in this filing, as its primary purpose is to report BlackRock's beneficial ownership.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cytek Biosciences, Inc.'s future performance or BlackRock's investment strategy beyond the current ownership disclosure.
Management Comments
- "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Statement from Spencer Fleming, Managing Director of BlackRock, Inc.)
Industry Context
This filing is a routine disclosure of a large institutional investor's stake and does not provide specific industry context for Cytek Biosciences, Inc. or its market position.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | Previous attorneys-in-fact under the April 30, 2023 Power of Attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | BlackRock, Inc. issued a new Power of Attorney, revoking a prior one dated April 30, 2023, to appoint or reconfirm authorized signatories for compliance filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy/Authorization | BlackRock, Inc. executed a new Power of Attorney on January 21, 2025, which revokes a previous Power of Attorney dated April 30, 2023. This document authorizes specific individuals to execute and file various SEC and other regulatory documents on behalf of BlackRock and its direct and indirect subsidiaries and affiliates. | 2025-01-21 | This internal governance change streamlines BlackRock's compliance processes by formally designating individuals authorized to sign and file regulatory documents, ensuring adherence to reporting requirements. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can be interpreted as a vote of confidence in the company.
- Management: Awareness of a large, passive institutional holder, which typically implies a stable shareholder base not seeking to influence control.
Next Steps
- BlackRock, Inc. will continue to file amendments to Schedule 13G as required by SEC regulations if there are material changes to its beneficial ownership stake in Cytek Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution of the new Power of Attorney by BlackRock, Inc., revoking a prior one. |
| 2025-06-30 | Date of event which requires filing of this statement, representing the beneficial ownership reporting period end date for BlackRock's stake in Cytek Biosciences, Inc. |
| 2025-07-18 | Date of signature for the Schedule 13G Amendment No. 4 filing by BlackRock, Inc. |
Keywords
Cytek Biosciences, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, CYTK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.